Onkológia 3/2025
Imunotherapy of malignant lymphomas in senility
The aging of the population is associated with an increased incidence of malignant lymphoproliferative diseases. Older age and associated diseases complicate the selection of effective treatment modalities. However, recent years have brought significant improvements in treatment outcomes even in the group of patients with malignant lymphomas. Reduction of intensive chemotherapy, monoclonal antibodies, cell therapy and immunotherapy offer effective and less expensive treatment options for elderly and frail patients.
Keywords: malignant lymphomas, senility, frailty, comorbidity